Hold Or Fold? IsoRay, Inc. (ISR) and Lpath, Inc. (LPTN)

Posted by Saimoon May 21, 2015 0 Comment 1510 views


New York, NY – GDP INSIDER  –  05/21/2014.

This article discusses two companies: IsoRay, Inc. (NYSEMKT:ISR) and Lpath, Inc. (NASDAQ:LPTN)

IsoRay, Inc. (NYSEMKT:ISR) saw solid gains yesterday with the stock soaring a whopping 93.79 % or $1.51 to close at $3.12, after hitting a new 52 week high of $3.38 during the day on very heavy trading of 50.34 million shares compared with its three month average trading volume of 0.797 million. The developer and marketer of isotope-based medical products and devices for the treatment of cancer started to surge after it posted improved results of using Cesium-131 seeds in the treatment of lung cancer. The study showed that there were no noticeable side effects and the survival rate at five years was outstanding for Cesium-131 group. Yesterday’s gains have pushed the total increase in the value of the stock so far this year to 113.70%. The RSI did surge to 84.27 following the increase and the MFI is 94.67. The stock could go through a minor correction with these technical in or close to the level of concern.  However, our reports show that the stock still has upside. If IsoRay, Inc makes further gains, it should enter a higher trading range making it a hold or profit-take at this time.

Can IsoRay, Inc Maintain Its Current Gains? Take A Look At The Fundamentals With Free ISR Analysis.

Lpath, Inc. (NASDAQ:LPTN) took an unexpected correction yesterday plummeting 79.82% or $1.365 to close at $0.345 on massive trading of 6.297 million shares, compared to its three month average trading volume of 44.87K. That being said, the situation could have been much worse for the California-based lipidomic-based therapeutics antibodies developer, as Lpath, Inc dropped to a new 52 week low of $0.32 during intraday trading. The drop was triggered after the company reported mid-stage study test failures on its experimental drug used to treat age-related macular degeneration, a leading cause of blindness among seniors. The shares are down over 88% over the past three months and by 82% over the last five days. Over the last 52 weeks, Lpath, Inc has lost more than 90% of its value and its continuing decline has depressed its RSI to 5.30.The MFI indicator is low at 3.12, also not a positive indicator of momentum and interest in the stock. Despite the low RSI, the stock’s MACD is still diverging downwards and with negative revenue growth of -52.90% and diluted EPS of -$0.89, the stock does not look like it has yet reached its lowest point, making it a risky investment at this time.

Can Lpath, Inc.Turn Things Around? Take A Look At Its Technical Indicators With Free LPTN Analysis.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.

 

 


Write Your Comment